CORT vs PTGX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CORT · Corcept Therapeutics$63.62 ▼ 2.09%
PTGX · Protagonist Therapeutics$121.40 ▼ 2.11%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CORT -18.1%
- PTGX +38.4%
Head to head
| Metric | CORT | PTGX |
|---|---|---|
| Price | $63.62 | $121.40 |
| Change today | ▼ 2.09% | ▼ 2.11% |
| Market cap | $6.96B | $7.92B |
| Return, 3 months | -48.4% | -21.5% |
| Return, year to date | +82.8% | +39.0% |
| Return, 1 year | -17.7% | +42.2% |
| P/E (TTM) | 47.8 | 25.7 |
| P/B | 8.4 | 7.3 |
| P/E percentile vs own 5y | 69th | 78th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +64.0% | +5,723.6% |
| Net profit growth (YoY) | +544.6% | +659.3% |
| Gross margin | 98.5% | 99.6% |
| Operating margin | 11.5% | 58.6% |
| Net margin | 16.5% | 62.0% |
| Return on equity | 21.7% | 39.6% |
| Analyst target vs. price | +161.4% | +48.3% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 21 | 32 |
| 30-day volatility | 78.5% | 41.1% |
| Max drawdown, 1 year | -63.5% | -23.5% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PTGX is the largest of the group by market value.
- PTGX has returned the most over the past year.
- PTGX carries the lowest trailing P/E.
- PTGX is growing revenue fastest.
- PTGX keeps the most profit per dollar of sales.
- PTGX has been the calmest stock over the last 30 days.